| pubmed-article:17947486 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17947486 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17947486 | lifeskim:mentions | umls-concept:C0877373 | lld:lifeskim |
| pubmed-article:17947486 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:17947486 | lifeskim:mentions | umls-concept:C1721684 | lld:lifeskim |
| pubmed-article:17947486 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:17947486 | pubmed:issue | 20 | lld:pubmed |
| pubmed-article:17947486 | pubmed:dateCreated | 2007-10-19 | lld:pubmed |
| pubmed-article:17947486 | pubmed:abstractText | To assess the safety and tolerability, pharmacokinetics, and early evidence of antitumor activity of escalating doses of lexatumumab (HGS-ETR2), a fully human agonistic monoclonal antibody which targets and activates the tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) in patients with advanced solid malignancies. | lld:pubmed |
| pubmed-article:17947486 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17947486 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17947486 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17947486 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17947486 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17947486 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17947486 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17947486 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17947486 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17947486 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:CalvertHilary... | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:JudsonIanI | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:PlummerRuthR | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:HalpernWendyW | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:KayeStanS | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:BarrettMaryM | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:FoxNorma... | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:PaceySimonS | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:AttardGerhard... | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:PerrettRebecc... | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:CoreyAlfredA | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:LiLouiseL | lld:pubmed |
| pubmed-article:17947486 | pubmed:author | pubmed-author:RazakAlbiruni... | lld:pubmed |
| pubmed-article:17947486 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17947486 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17947486 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:17947486 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17947486 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17947486 | pubmed:pagination | 6187-94 | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:meshHeading | pubmed-meshheading:17947486... | lld:pubmed |
| pubmed-article:17947486 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17947486 | pubmed:articleTitle | Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. | lld:pubmed |
| pubmed-article:17947486 | pubmed:affiliation | Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom. Ruth.Plummer@newcastle.ac.uk | lld:pubmed |
| pubmed-article:17947486 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17947486 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17947486 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17947486 | lld:pubmed |
